| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 232,0 k € | +247.5% | 66,8 k € | -10.6% | 74,7 k € | -60.0% | 186,6 k € | +46.5% | 127,4 k € | +250.6% | -84,6 k € | |
| EBITDA | -145,6 k € | +56.1% | -332,0 k € | -18.7% | -279,7 k € | -36.7% | -204,7 k € | -510.8% | -33,5 k € | +86.7% | -252,0 k € | |
| Operating profit | -1,9 M € | +5.1% | -2,0 M € | -2.1% | -2,0 M € | +38.5% | -3,3 M € | -74.0% | -1,9 M € | -54.1% | -1,2 M € | |
| Profit/loss | -921,3 k € | -10.6% | -832,6 k € | +9.8% | -922,7 k € | +40.4% | -1,5 M € | -54.0% | -1,0 M € | -68.5% | -597,1 k € | |
| Equity | 1,6 M € | -27.5% | 2,2 M € | -27.3% | 3,0 M € | -22.5% | 3,8 M € | +87.7% | 2,0 M € | -33.0% | 3,1 M € | |
| Total assets | 2,2 M € | -27.1% | 3,0 M € | -16.8% | 3,6 M € | -21.0% | 4,5 M € | +80.3% | 2,5 M € | -30.2% | 3,6 M € | |
| Cash | 669,9 k € | -0.9% | 675,7 k € | +215.3% | 214,3 k € | -95.0% | 4,3 M € | +132.5% | 1,8 M € | -47.2% | 3,5 M € | |
| Debts | 585,8 k € | -25.9% | 791,1 k € | +37.1% | 577,1 k € | -12.4% | 658,5 k € | +59.4% | 413,2 k € | -20.2% | 517,8 k € | |
| Staff | 5,2 | 5,8 | 5,5 | 6 | 3,4 | 2,8 | ||||||
Private limited company · Charleroi · incorporated on 29/08/2019 · 5,2 ETP
Private limited company loss-making in the latest fiscal year.
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
Inhatarget Therapeutics is a Private limited company incorporated in 2019. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Charleroi. It employs on average 5,2 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette